Here are five key points:
1. Australia issued the patent.
2. The one-hour test is designed to accurately pinpoint Methicillin-resistant Staphylococcus aureus.
3. The technology can also detect the common antibiotic-resistant Coagulase Negative Staphylococcus.
4. Other tests do not detect CNS, which is much more common than MRSA.
5. Next, the institutions hope to receive U.S. patent approval.
More articles on quality & infection control:
CDC allots additional $60M to fight Zika: 5 notes
Failing to openly disclose adverse events may negatively impact surgeons: 8 key takeaways
Reduce medical errors by 19% & improve financial outcomes by 15% — 5 findings on team training
